BR112012004395B8 - plasmídeo fator 1 derivado de célula de estroma (sdf-1) e preparação injetável compreendendo referido plasmídeo - Google Patents

plasmídeo fator 1 derivado de célula de estroma (sdf-1) e preparação injetável compreendendo referido plasmídeo

Info

Publication number
BR112012004395B8
BR112012004395B8 BR112012004395A BR112012004395A BR112012004395B8 BR 112012004395 B8 BR112012004395 B8 BR 112012004395B8 BR 112012004395 A BR112012004395 A BR 112012004395A BR 112012004395 A BR112012004395 A BR 112012004395A BR 112012004395 B8 BR112012004395 B8 BR 112012004395B8
Authority
BR
Brazil
Prior art keywords
plasmid
sdf
left ventricular
injectable preparation
derived factor
Prior art date
Application number
BR112012004395A
Other languages
English (en)
Other versions
BR112012004395A2 (pt
BR112012004395B1 (pt
Inventor
Pastore Joseph
S Penn Marc
Aras Rahul
R Miller Timothy
Original Assignee
Cleveland Clinic Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Found filed Critical Cleveland Clinic Found
Publication of BR112012004395A2 publication Critical patent/BR112012004395A2/pt
Publication of BR112012004395B1 publication Critical patent/BR112012004395B1/pt
Publication of BR112012004395B8 publication Critical patent/BR112012004395B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

plasmídeo sdf-1, preparação injetável e uso da referida preparação. um método de tratar uma cardiomiopatia em um indivíduo inclui administrar diretamente ou expressar localmente em uma região de peri-infarto e/ou enfraquecida, isquêmica, do tecido do miocárdio do indivíduo, uma quantidade de sdf-1 eficaz para causar melhoria funcional em pelo menos um dos seguintes parâmetros: volume ventricular esquerdo, área ventricular esquerda, dimensão ventricular esquerda, função cardíaca, teste de caminhada de 6 minutos, ou classificação funcional da new york heart association (nyha).
BR112012004395A 2009-08-28 2010-08-30 plasmídeo fator 1 derivado de célula de estroma (sdf-1) e preparação injetável compreendendo referido plasmídeo BR112012004395B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23777509P 2009-08-28 2009-08-28
US61/237,775 2009-08-28
US33421610P 2010-05-13 2010-05-13
US61/334,216 2010-05-13
PCT/US2010/047175 WO2011026041A2 (en) 2009-08-28 2010-08-30 Sdf-1 delivery for treating ischemic tissue

Publications (3)

Publication Number Publication Date
BR112012004395A2 BR112012004395A2 (pt) 2016-11-16
BR112012004395B1 BR112012004395B1 (pt) 2021-01-12
BR112012004395B8 true BR112012004395B8 (pt) 2021-05-25

Family

ID=43628693

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012004395A BR112012004395B8 (pt) 2009-08-28 2010-08-30 plasmídeo fator 1 derivado de célula de estroma (sdf-1) e preparação injetável compreendendo referido plasmídeo

Country Status (9)

Country Link
US (5) US20120283315A1 (pt)
EP (1) EP2473196B1 (pt)
JP (1) JP5856059B2 (pt)
CN (1) CN102740894B (pt)
AU (1) AU2010286511B2 (pt)
BR (1) BR112012004395B8 (pt)
CA (1) CA2772610C (pt)
MX (1) MX357779B (pt)
WO (1) WO2011026041A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
CA2682469A1 (en) 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Method of treating ischemic disorders
AU2008338525B2 (en) 2007-12-14 2015-04-02 Juventas Therapeutics, Inc. Compositions and methods of promoting wound healing
CN102740894B (zh) 2009-08-28 2015-07-15 克利夫兰临床医学基金会 用于治疗缺血组织的sdf-1递送
WO2011106234A1 (en) 2010-02-25 2011-09-01 Provasculon, Inc. Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
EP2627342B1 (en) * 2010-10-14 2016-08-24 University Of Central Florida Research Foundation, Inc. Cardiac induced pluripotent stem cells and methods of use in repair and regeneration of myocardium
US20130136729A1 (en) * 2011-11-11 2013-05-30 University of Virginia Patent Foundation, d/b/a University of Virginia Licensing & Ventures Group Compositions and methods for targeting and treating diseases and injuries using adeno-associated virus vectors
CN105264071B (zh) * 2013-03-15 2020-05-19 克利夫兰临床医学基金会 用于治疗缺血组织的sdf-1递送
EP2968608A4 (en) * 2013-03-15 2016-10-26 Cleveland Clinic Foundation RETROGRADE ADMINISTRATION OF SDF-1 FOR THE TREATMENT OF MYOCARDIAL INFARCTION
US20160331809A1 (en) * 2013-03-15 2016-11-17 Juventas Therapeutics, Inc. The use of sdf-1 to mitigate scar formation
US20160278810A1 (en) 2013-05-31 2016-09-29 Mark Edmund Richey Vaginal surgical apparatus
US10166044B1 (en) 2013-05-31 2019-01-01 Freshwater Bay Industries, Llc Apparatus for repositioning the vagina, cervix, uterus and pelvic floor and method to secure same
US20170049856A1 (en) * 2014-04-28 2017-02-23 Juventas Therapeutics, Inc. Sdf-1 delivery for treating advanced ischemic cardiomyopathy
AU2015256383B2 (en) 2014-05-08 2020-05-21 Wake Forest University Health Sciences Methods of treating incontinence and other sphincter deficiency disorders
ES2864373T3 (es) 2014-12-23 2021-10-13 Ilya Pharma Ab Métodos para la cicatrización
KR20180069081A (ko) 2015-11-11 2018-06-22 인트렉손 코포레이션 심장 이상 및 기타 병리 이상의 치료를 위한 복수의 생물학적으로 활성화된 폴리펩티드를 단일 벡터로부터 발현하기 위한 조성물 및 방법
AU2018244776B2 (en) * 2017-03-30 2023-12-14 Wake Forest University Health Sciences Methods of treatment for kidney disease
US11583571B2 (en) 2017-05-13 2023-02-21 The Johns Hopkins University Stromal derived factor 1 and its use in the prevention and treatment of erectile dysfunction
US11654181B2 (en) 2017-08-11 2023-05-23 Wake Forest University Health Sciences Use of CXCL12 for therapy after prostate surgery

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
AU650085B2 (en) 1990-11-13 1994-06-09 Immunex Corporation Bifunctional selectable fusion genes
US5197985A (en) 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US20020031803A1 (en) * 1997-06-20 2002-03-14 Cooper Mark J. Expression system for production of therapeutic proteins
US5602301A (en) 1993-11-16 1997-02-11 Indiana University Foundation Non-human mammal having a graft and methods of delivering protein to myocardial tissue
WO1996026742A1 (en) 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US5980887A (en) 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
JP2001509168A (ja) * 1997-01-29 2001-07-10 コーネル リサーチ ファウンデーション、インコーポレイティッド 血管新生を誘導するためのアデノウイルスベクターの多部位送達
DE69837760T3 (de) 1997-06-13 2012-06-21 Genentech, Inc. Proteinreinigung mittels chromatographie und darauffolgende filtration auf beladener schicht
MXPA00003885A (es) 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
CN1295617A (zh) 1998-02-06 2001-05-16 科莱特诺医疗公司 血管生成因子－血管内皮细胞生长因子vegf的突变体
EP1061800A4 (en) 1998-03-09 2004-10-06 Caritas St Elizabeths Boston COMPOSITIONS AND METHODS FOR MODULATING THE VASCULARIZATION
US6676937B1 (en) 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
DK1068357T3 (da) 1998-03-30 2011-12-12 Northwest Biotherapeutics Inc Terapeutiske og diagnostiske anvendelser baseret på CXCR-4-genets rolle i tumorgenese
US20020107195A1 (en) 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
IL125532A0 (en) 1998-07-27 1999-03-12 Yeda Res & Dev Hematopoietic cell composition for use in transplantation
AU5241099A (en) 1998-07-31 2000-02-21 Trustees Of Columbia University In The City Of New York, The Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
WO2000015285A1 (en) * 1998-09-14 2000-03-23 Mirus Corporation A process for delivering nucleic acids to cardiac tissue
DE19844479C1 (de) 1998-09-28 2000-04-13 Siemens Ag Integrierter Speicher mit einem differentiellen Leseverstärker
US7399751B2 (en) 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
EP1013770A1 (en) * 1998-12-23 2000-06-28 Université Louis Pasteur de Strasbourg Non-viral transfection vector
DE19900743A1 (de) * 1999-01-12 2000-07-13 Aventis Pharma Gmbh Neue komplexbildende Proteine
AU3347000A (en) 1999-01-19 2000-08-01 Children's Hospital Of Philadelphia, The Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
WO2000050048A2 (en) 1999-02-26 2000-08-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Bone marrow transplantation for hepatic regeneration and repair
US20050153451A1 (en) * 1999-02-26 2005-07-14 Wolff Jon A. Intravascular delivery of non-viral nucleic acid
EP1041148A1 (en) 1999-04-02 2000-10-04 Mogen International N.V. Pathogen inducible promoter
US6448054B1 (en) 1999-04-08 2002-09-10 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
US7125856B1 (en) 1999-04-15 2006-10-24 St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
AU4801501A (en) * 2000-05-26 2001-11-29 Transgene S.A. Complex for transferring an anionic substance of interest into a cell
CA2810249A1 (en) 2000-06-05 2001-12-13 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cell to improve myocardial function after ischemic injury
US20020061587A1 (en) * 2000-07-31 2002-05-23 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium
CA2386103A1 (en) * 2000-08-04 2002-02-14 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
US7402567B2 (en) 2000-10-27 2008-07-22 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
US20020094327A1 (en) 2000-11-05 2002-07-18 Petersen Bryon E. Targeting pluripotent stem cells to tissues
US7405076B2 (en) 2000-11-14 2008-07-29 Universite Libre De Bruxelles Generation and use of dendritic cells
MXPA03004913A (es) 2000-12-01 2003-09-05 Schering Corp Usos de genes de mamifero y reactivos relacionados.
AR027161A1 (es) * 2001-05-15 2003-03-19 Bio Sidus S A Metodo para inducir la proliferacion neovascular y regeneracion tisular
US7399740B2 (en) 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
WO2003014336A1 (fr) 2001-08-07 2003-02-20 Kirin Beer Kabushiki Kaisha Procede de preparation de cellules souches hematopoietiques multipotentes
AU2002325711C1 (en) 2001-09-14 2008-05-29 Stem Cell Therapeutics Inc. Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
US7402724B2 (en) 2002-01-04 2008-07-22 Mayo Foundation For Medical Education And Research Longevity and PAPP-A
WO2003059375A1 (fr) 2002-01-17 2003-07-24 Cardio Incorporated Therapie complexe pour la regeneration des tissus
FR2843697B1 (fr) * 2002-08-26 2005-12-09 Sod Conseils Rech Applic L'heterocarpine, une proteine d'origine vegetale aux proprietes anticancereuses
US7396537B1 (en) 2002-02-28 2008-07-08 The Trustees Of The University Of Pennsylvania Cell delivery patch for myocardial tissue engineering
IL164079A0 (en) 2002-03-15 2005-12-18 Us Dept Veterans Affairs Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20040037811A1 (en) 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
US20040161412A1 (en) * 2002-08-22 2004-08-19 The Cleveland Clinic Foundation Cell-based VEGF delivery
US20050271639A1 (en) 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
JP2004099471A (ja) 2002-09-05 2004-04-02 Cardio Corp 心筋梗塞および心不全の治療薬
WO2004033396A2 (en) 2002-10-08 2004-04-22 American National Red Cross Method for enriching adherent monocyte populations
JP2006505380A (ja) 2002-11-05 2006-02-16 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 間葉幹細胞およびその使用方法
EP1583422B1 (en) 2002-12-05 2016-03-30 Case Western Reserve University Cell-based therapies for ischemia
WO2004074494A1 (ja) * 2003-02-19 2004-09-02 Dnavec Research Inc. 虚血疾患の治療方法
AU2003902037A0 (en) 2003-04-24 2003-05-15 Mclachlan, Craig Method for tissue growth
US20050104072A1 (en) 2003-08-14 2005-05-19 Slater David B.Jr. Localized annealing of metal-silicon carbide ohmic contacts and devices so formed
US7396680B2 (en) 2003-10-31 2008-07-08 Cornell Research Foundation, Inc. Stem cell-specific promoters and their use
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
US8071364B2 (en) * 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
ATE551066T1 (de) 2004-06-21 2012-04-15 Cleveland Clinic Foundation Ccr-liganden für stammzellen-homing
EP1803464A4 (en) 2004-09-17 2009-09-09 Cellgentech Inc TOPICAL PREPARATION FOR THE TREATMENT OF SKIN DISEASES
JP2008514640A (ja) * 2004-09-27 2008-05-08 バレンティス，インコーポレイティド 炎症性疾患治療のための製剤と方法
US20060105950A1 (en) 2004-10-25 2006-05-18 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Morphogen compositions and use thereof to treat wounds
US20060166361A1 (en) 2004-12-21 2006-07-27 Agnieszka Seyda Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
US7951632B1 (en) 2005-01-26 2011-05-31 University Of Central Florida Optical device and method of making
GB2424312B (en) 2005-03-14 2010-03-03 Denso Corp Method of forming an ohmic contact in wide band semiconductor
KR20080046658A (ko) 2005-09-16 2008-05-27 크리 인코포레이티드 실리콘 카바이드 전력 소자들을 그 상에 가지는 반도체웨이퍼들의 가공방법들
WO2007081964A2 (en) 2006-01-10 2007-07-19 Cree, Inc. Silicon carbide dimpled substrate
US20070173471A1 (en) 2006-01-24 2007-07-26 Losordo Douglas W Morphogen compositions and methods of use thereof to treat heart disorders
US7405195B2 (en) 2006-03-27 2008-07-29 Natural Beauty Bio-Technology Limited Cosmetic compositions
CA2682469A1 (en) 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Method of treating ischemic disorders
AU2008338525B2 (en) 2007-12-14 2015-04-02 Juventas Therapeutics, Inc. Compositions and methods of promoting wound healing
CN102740894B (zh) 2009-08-28 2015-07-15 克利夫兰临床医学基金会 用于治疗缺血组织的sdf-1递送
WO2012037083A2 (en) 2010-09-15 2012-03-22 The Cleveland Clinic Foundation Compositions and method for promoting musculoskeletal repair
US20120068161A1 (en) 2010-09-16 2012-03-22 Lee Keon-Jae Method for forming graphene using laser beam, graphene semiconductor manufactured by the same, and graphene transistor having graphene semiconductor
JP5569376B2 (ja) 2010-12-07 2014-08-13 住友電気工業株式会社 半導体装置の製造方法

Also Published As

Publication number Publication date
CN102740894B (zh) 2015-07-15
MX357779B (es) 2018-07-24
MX2012002610A (es) 2012-08-23
WO2011026041A9 (en) 2011-07-21
CA2772610C (en) 2018-01-23
EP2473196A2 (en) 2012-07-11
US8513007B2 (en) 2013-08-20
WO2011026041A2 (en) 2011-03-03
US20120289585A1 (en) 2012-11-15
BR112012004395A2 (pt) 2016-11-16
US8513213B2 (en) 2013-08-20
BR112012004395B1 (pt) 2021-01-12
CA2772610A1 (en) 2011-03-03
US20120283315A1 (en) 2012-11-08
AU2010286511A1 (en) 2012-04-12
EP2473196A4 (en) 2015-01-07
JP5856059B2 (ja) 2016-02-09
CN102740894A (zh) 2012-10-17
AU2010286511B2 (en) 2016-05-26
EP2473196B1 (en) 2017-05-31
JP2013503202A (ja) 2013-01-31
US20130303597A1 (en) 2013-11-14
US20120289586A1 (en) 2012-11-15
US20140135383A1 (en) 2014-05-15
US9844581B2 (en) 2017-12-19
US8883756B2 (en) 2014-11-11

Similar Documents

Publication Publication Date Title
BR112012004395B8 (pt) plasmídeo fator 1 derivado de célula de estroma (sdf-1) e preparação injetável compreendendo referido plasmídeo
Khan Atrial stunning: determinants and cellular mechanisms
BR112013003186A2 (pt) composições e métodos para tratamento de doença cardiovascular
BR112018013979A2 (pt) composições em gel para liberação transdérmica para maximizar as concentrações de fármacos no estrato córneo e no soro e métodos de uso dos mesmos
BR112016010193A2 (pt) materiais de crescimento interno de tecido e método de utilização dos mesmos
BRPI0512583A (pt) composições e métodos de produção das mesmas, de liberação de agente ativo para e através do tecido da epiderme de pessoa ou animal e de tratamento de paciente que sofre de onicomicose, de psorìase de unha e de infecções
WO2008096268A3 (en) Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery
EP1742643A4 (en) MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOKASE EXPRESSION
EP4124346A3 (en) Compositions and methods for treating diseases
Traynor et al. Effect of a novel penetration enhancer on the ungual permeation of two antifungal agents
WO2014153160A3 (en) METHOD OF ENHANCING THE BIODISTRIBUTION AND TISSUE TARGETING PROPERTIES OF THERAPEUTIC CeO2 PARTICLES VIA NANO-ENCAPSULATION AND COATING
Chao et al. Oxidative pathophysiology following volumetric muscle loss injury in a porcine model
Manda et al. Iontophoretic drug delivery for the treatment of scars
CY1115619T1 (el) Αποκλειστες διαυλου ασβεστιου φαινυλαλκυλ αμινης βραχειας δρασεως και χρησεις αυτων
JP2017522392A5 (pt)
PE20110066A1 (es) Dronedarona para la prevencion de la cardioversion
BRPI0410844A (pt) fator de crescimento de fibroblasto de codificação de plasmìdeo para o tratamento de defeitos angiogênicos associados com hipercolesterolemia ou diabetes
Woo et al. Myocardial regeneration therapy for ischemic cardiomyopathy with cyclin A2
Agnić et al. Isoflurane post-conditioning stimulates the proliferative phase of myocardial recovery in an ischemia-reperfusion model of heart injury in rats
WO2010077364A3 (en) Stroke-generated angiogenesis enhancers and uses thereof
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
BRPI1009003A2 (pt) "método para expressão recombinante de um ccn1 humano, uso de um ccn1 humano, anticorpo contra ccn1 humano, uso de um anticorpo contra ccn1 humano, método para a fabricação de um medicamento para o tratamento de doenças e composição farmacêutica"
Nouchi et al. Chronic left atrial volume overload abbreviates the action potential duration of the canine pulmonary vein myocardium via activation of IK channel
EA201591737A1 (ru) Доставка sdf-1 для лечения ишемизированной ткани
US11813262B2 (en) Compositions and methods to increase muscular strength

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 38/19 (2006.01), A61K 9/00 (2006.01), A61K 31

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/08/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2685 DE 21-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.